BCP403

BCP403 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by Biocure Technology for the treatment of solid tumors. As a cell-based immunotherapy, it involves the genetic modification of a patient's T cells to express a synthetic receptor designed to recognize and eliminate cancer cells. While the specific molecular target for BCP403 has not been publicly disclosed by the developer, the program is part of Biocure's broader effort to expand the efficacy of CAR-T therapies beyond hematological malignancies into the more challenging environment of solid tumors. The drug is currently in the preclinical stage of development, focusing on identifying effective antigens and overcoming the immunosuppressive microenvironment characteristic of solid tumor tissues.